Uncategorized
Santen, Tracon to develop anti-endoglin antibodies in ophthalmology
Santen Pharmaceutical Co. has entered into an exclusive agreement with Tracon Pharmaceuticals for the development and global commercialization of Tracon’s anti-endoglin antibodies, including TRC105, in ophthalmology, according to a press release. TRC105 in combination with anti-VEGF products, as preclinical and clinical data have shown in oncology, has the potential to be a more effective treatment for conditions such as wet age-related macular degeneration than inhibiting VEGF alone, the release said.